NCT03517488 2022-12-01
DUET-2
Xencor, Inc.
Phase 1 Completed
150 enrolled
BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic
Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Anus Neoplasms, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Melanoma, Mesothelioma, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Thymoma, Thymus Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Neuroendocrine, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms